Unknown

Dataset Information

0

Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.


ABSTRACT: Triple-negative breast cancer (TNBC) is a leading cause of breast cancer death and is often associated with BRCA1 and BRCA2 mutation. Due to the lack of validated target molecules, no targeted therapy for TNBC is approved. Tissue factor (TF) is a common yet specific surface target receptor for cancer cells, tumor vascular endothelial cells, and cancer stem cells in several types of solid cancers, including breast cancer. Here, we report evidence supporting the idea that TF is a surface target in TNBC. We used in vitro cancer lines and in vivo tumor xenografts in mice, all with BRCA1 or BRCA2 mutations, derived from patients' tumors. We showed that TF is overexpressed on TNBC cells and tumor neovasculature in 50% to 85% of TNBC patients (n = 161) and in TNBC cell line-derived xenografts (CDX) and patient-derived xenografts (PDX) from mice, but was not detected in adjacent normal breast tissue. We then describe the development of a second-generation TF-targeting immunoconjugate (called L-ICON1, for lighter or light chain ICON) with improved efficacy and safety profiles compared with the original ICON. We showed that L-ICON1 kills TNBC cells in vitro via antibody-dependent cell-mediated cytotoxicity and can be used to treat human and murine TNBC CDX as well as PDX in vivo in orthotopic mouse models. Thus, TF could be a useful target for the development of immunotherapeutics for TNBC patients, with or without BRCA1 and BRCA2 mutations. Cancer Immunol Res; 6(6); 671-84. ©2018 AACR.

SUBMITTER: Hu Z 

PROVIDER: S-EPMC5984705 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.

Hu Zhiwei Z   Shen Rulong R   Campbell Amanda A   McMichael Elizabeth E   Yu Lianbo L   Ramaswamy Bhuvaneswari B   London Cheryl A CA   Xu Tian T   Carson William E WE  

Cancer immunology research 20180405 6


Triple-negative breast cancer (TNBC) is a leading cause of breast cancer death and is often associated with <i>BRCA1</i> and <i>BRCA2</i> mutation. Due to the lack of validated target molecules, no targeted therapy for TNBC is approved. Tissue factor (TF) is a common yet specific surface target receptor for cancer cells, tumor vascular endothelial cells, and cancer stem cells in several types of solid cancers, including breast cancer. Here, we report evidence supporting the idea that TF is a sur  ...[more]

Similar Datasets

| S-EPMC7028910 | biostudies-literature
| S-EPMC6360707 | biostudies-literature
| S-EPMC8705248 | biostudies-literature
| S-EPMC10055616 | biostudies-literature
| S-EPMC8401402 | biostudies-literature
| S-EPMC10605606 | biostudies-literature
| S-EPMC8801574 | biostudies-literature
| S-EPMC10474743 | biostudies-literature
| S-EPMC7433748 | biostudies-literature
| S-EPMC5768393 | biostudies-literature